CoChat

Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers

Open access
Goyal, Devendra, Tjandra, Donna, Migrino, Raymond Q., Giordani, Bruno, Syed, Zeeshan, Wiens, Jenna, Alzheimer's Disease Neuroimaging Initiative · 2018 · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Cited by 37

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Introduction: Models characterizing intermediate disease stages of Alzheimer's disease (AD) are needed to inform clinical care and prognosis. Current models, however, use only a small subset of available biomarkers, capturing only coarse changes along the complete spectrum of disease progression. We propose the use of machine learning techniques and clinical, biochemical, and neuroimaging biomarkers to characterize progression to AD. Methods: We used a large multimodal longitudinal data set of biomarkers and demographic and genotype information from 1624 participants from the Alzheimer's Disease Neuroimaging Initiative. Using hidden Markov models, we characterized intermediate disease stages. We validated inferred disease trajectories by comparing time to first clinical AD diagnosis. We trained an L2‐regularized logistic regression model to predict disease trajectory and evaluated its discriminative performance on a test set. Results: We identified 12 distinct disease states. Progression to AD occurred most often through one of two possible paths through these states. Paths differed in terms of rate of disease progression (by 5.44 years on average), amyloid and total‐tau (t‐tau) burden (by 10% and 69%, respectively), and hippocampal neurodegeneration (P < .001). On the test set, the predictive model achieved an area under the receiver operating characteristic curve of 0.85. Discussion: Progression to AD, in terms of biomarker trajectories, can be predicted based on participant‐specific factors. Such disease staging tools could help in targeting high‐risk patients for therapeutic intervention trials. As longitudinal data with richer features are collected, such models will help increase our understanding of the factors that drive the different trajectories of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.dadm.2018.06.007

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 37

Metadata

Authors
Goyal, D., Tjandra, D., Migrino, R. Q., Giordani, B., Syed, Z., Wiens, J., & Initiative, A. D. N.
Venue
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publisher
Wiley
Published
2018-01
Volume
10
Issue
1
Pages
629-637
ISSN
2352-8729 (ISSN-L)
OpenAlex
W2886957118
Cited by
37
References
12
FWCI
2.08
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers. https://app.cochat.ai/papers/10.1016/j.dadm.2018.06.007
The paper
Goyal, D., Tjandra, D., Migrino, R. Q., Giordani, B., Syed, Z., Wiens, J., & Initiative, A. D. N. (2018). Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://doi.org/10.1016/j.dadm.2018.06.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.